Belén Atienza Mateo-rekin lankidetzan egindako argitalpenak (10)

2024

  1. Subcutaneous vs intravenous abatacept in rheumatoid arthritis-interstitial lung disease. National multicentre study of 397 patients

    Seminars in Arthritis and Rheumatism, Vol. 68

2022

  1. Correction to: Ferraz-Amaro et al. SCORE2 Assessment in The Calculation of Cardiovascular Risk in Patients with Rheumatoid Arthritis (Diagnostics 2021, 11, 2363)

    Diagnostics

2021

  1. Combined use of QRISK3 and SCORE as predictors of carotid plaques in patients with rheumatoid arthritis

    Rheumatology (Oxford, England), Vol. 60, Núm. 6, pp. 2801-2807

  2. Disease activity influences the reclassification of rheumatoid arthritis into very high cardiovascular risk

    Arthritis Research and Therapy, Vol. 23, Núm. 1

  3. Long-term Follow-up and optimization of infliximab in refractory uveitis due to Behçet Disease: National study of 103 white patients

    Journal of Rheumatology, Vol. 48, Núm. 5, pp. 741-750

  4. Moderate and high disease activity predicts the development of carotid plaque in rheumatoid arthritis patients without classic cardiovascular risk factors: Six years follow-up study

    Journal of Clinical Medicine, Vol. 10, Núm. 21

  5. SCORE2 assessment in the calculation of cardiovascular risk in patients with rheumatoid arthritis

    Diagnostics, Vol. 11, Núm. 12

2020

  1. Carotid plaques as predictors of cardiovascular events in patients with Rheumatoid Arthritis. Results from a 5-year-prospective follow-up study

    Seminars in Arthritis and Rheumatism, Vol. 50, Núm. 6, pp. 1333-1338

2019

  1. Anti-IL6-Receptor Tocilizumab in Refractory and Noninfectious Uveitic Cystoid Macular Edema: Multicenter Study of 25 Patients

    American Journal of Ophthalmology, Vol. 200, pp. 85-94

2018

  1. Anti-interleukin 6 receptor tocilizumab in refractory uveitis associated with Behçet's disease: Multicentre retrospective study

    Rheumatology (United Kingdom), Vol. 57, Núm. 5, pp. 856-864